Skip to main content

Shift is developing a pipeline of product candidates for conventional indications.

Discover
Overview.

Shift has identified targets that are both anti-aging and pro-aging. We are building sentinel programs around each of these activity states.

For over expression of our first anti-aging target (SB-000), we are utilizing AAV as a gene therapy modality to repair age-related hearing loss in a privileged compartment. For inhibition of our first pro-aging target, we are employing RNAi for knockdown starting in liver for fibrosis with plans to expand into additional tissue types. We are further exemplifying a tool small molecule to target SB-101 systematically for systemic sclerosis.

190

Genes Identified

siRNA provides a fast proven means for target validation in a large patient population, while the small molecule approach enables PoC to initiate a small molecule discovery program as the target is further validated.

So far Shift’s platform has identified 150 anti-aging and 40 pro-aging targets, with 11 targets outperforming OSK in aged fibroblasts by in vitro epigenetic rejuvenation.

UMAP plot showing rejuvenation (blue) or aging (red) of single cell aging clock AC3 in response to a panel of 1500 single gene interventions.
Sentinel programs.